Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

“The patient population recruited into this study includes those ovarian cancer patients that have platinum resistant/refractory disease, defined as disease progression/relapse within 6 months following the last administered dose of platinum therapy (resistant), or lack of response or disease progression while receiving the most recent platinum based therapy (refractory), respectively. Patients may or may not have had additional treatment (e.g., Doxil) prior to entry in this study.”

Not out of options, but darn close. Yeah, I think when he mentioned “placebo effect,” he may have meant more correctly spontaneous remission. I think it’s the “doc” who keeps saying the word “placebo.”

It’s an open label study. Not aware of a PhII where patients exhausted all standard care and some experimental that required a placebo,...